Directorio

We created the Registry for Brain Health to help you improve your brain health and get involved in research studies. The number of people in North Carolina affected by memory disorders, such as Alzheimer's disease and other forms of dementia, is going up. To change that, we must work together, stay informed, and get involved. We are enrolling both people who have memory problems and people who are healthy and do not have memory problems.

We are doing this study to find out if an investigational called Daromun (the study drug) is a safe and effective treatment for melanoma. We want to know if treating people with the drug before surgery to remove tumors can lower the chance of cancer recurrence.

We are doing this study to find out if combining psychological skills and a procedure called neurostimulation during one clinic session can help reduce negative emotions and problems with dealing with emotions in both a laboratory setting and in a person's everyday life.

In this study, you will have a virtual visit, which is like a video call. During the visit, you will share information about your past activities, such as how many steps you have walked, from your smartphone. If you have a smartwatch, the study may also collect health information like your heart rate and blood oxygen level. You will also answer a short online survey. The whole visit will take about 20 to 40 minutes.

We are doing this study to find out if a drug called satralizumab (the study drug) is a safe and effective option for people with autoimmune encephalitis.

We are doing this study to collect information about the speeds of eye and head movements in healthy children and young adults. This information will help us establish normal values related to these movement speeds and patterns. If we have a measure of what is normal, this will help us determine the severity of symptoms or injury for people who are treated for concussions.

We are doing this study to find out if an experimental drug called NST-6179 (the study drug) is a a safe and effective option for patients with intestinal failure-associated liver disease (IFALD).

We are doing this study to compare two commonly used treatment choices for early-stage breast cancer in premenopausal women. We want to know if either option is a better choice than the other.